Clinical studies recruiting near North Dartmouth

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Wi
Phase 2 · National Cancer Institute (NCI) · NCT05564390 Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small C
Phase 3 · NRG Oncology · NCT05624996 Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally A
Phase 1/Phase 2 · National Cancer Institute (NCI) · NCT04172532 Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)
Phase 1/Phase 2 · Sangamo Therapeutics · NCT06980948 Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS
Phase 3 · Eli Lilly and Company · NCT06890598 Quality of Pediatric Resuscitation in a Multicenter Collaborative
Phase N/A · Children's Hospital of Philadelphia · NCT02708134 Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Phase 3 · NRG Oncology · NCT05946213 Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Ca
Phase N/A · Duke University · NCT04278404 Nectero EAST System Clinical Study
Phase 2/Phase 3 · Nectero Medical, Inc. · NCT06001918 Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patient
Phase 2 · NRG Oncology · NCT06532279 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Phase 2/Phase 3 · NRG Oncology · NCT05174169 Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Canc
Phase 3 · Alliance for Clinical Trials in Oncology · NCT06632327 Zenith® Fenestrated+ Clinical Study
NA · Cook Research Incorporated · NCT04875429 ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathol
Phase 3 · Alliance for Clinical Trials in Oncology · NCT06876714 Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or
Phase 3 · Canadian Cancer Trials Group · NCT03550391 Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SL
Phase 3 · National Cancer Institute (NCI) · NCT04269902 A Study to Assess Growth in Children With Idiopathic Short Stature
Phase N/A · BioMarin Pharmaceutical · NCT06309979 Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and S
Phase 3 · Canadian Cancer Trials Group · NCT06592924 Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely
Phase 3 · NRG Oncology · NCT03180268 A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KR
Phase 3 · Eli Lilly and Company · NCT06119581 Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidin
Phase 2 · National Cancer Institute (NCI) · NCT05554393 An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerabilit
Phase 3 · Novartis Pharmaceuticals · NCT07517263 Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Phase 2 · SWOG Cancer Research Network · NCT05633615 Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Phase 3 · Revolution Medicines, Inc. · NCT06881784 A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherap
Phase 2/Phase 3 · AbbVie · NCT07155187 Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Inva
Phase 2 · National Cancer Institute (NCI) · NCT07061964 Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
Phase 3 · Children's Oncology Group · NCT05235165 De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Eq
Phase 3 · NRG Oncology · NCT04852887 I-DECIDE After Bronchiolitis Hospitalization
NA · Seattle Children's Hospital · NCT07243652 Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cance
Phase 2/Phase 3 · NRG Oncology · NCT04333537

Look up another city

Look up another condition